The Impact of Glomerular Disorders on Bone Quality and Strength
Part of paid clinical trials in New York, New York.
- Sponsor
- Columbia University
- Study ID
- NCT04528446
- Status
- Recruiting
Conditions
- Bone Diseases, Metabolic
- Bone Fracture
- Glomerular Disease
Eligibility Criteria
- Sex
- ALL
- Age
- 5 Years - 55 Years
- Healthy Volunteers
- Accepted
Interventions
- Dual-energy X-ray absorptiometry — RADIATIONDXA whole body, hip, spine, and radius at baseline, and 12-month visit.
- High Resolution Peripheral Quantitative Computed Tomography (HR-pQCT) — RADIATIONHR-pQCT of the radius and tibia at baseline, and 12-month visit.
- Blood draw and Urine collection — OTHERThe blood draw can be completed +/- 3 weeks from baseline or 12-month visit.
- Questionnaires — OTHERQuestionnaires regarding fracture history, physical activity and dietary intake at baseline, and 12-month visit.
Study Details
The primary objectives of this study are to: (1) determine the impact of glomerular disease on bone strength and (2) investigate the pathophysiologic underpinnings of impaired bone strength in glomerular disease.
Key Dates
- Start date
- Jun 14, 2019
- Status verified
- Jun 2024
- Primary completion
- Dec 31, 2024
- Completion
- Dec 31, 2024
Study Design
- Enrollment
- 270 participants (estimated)
Arms
- Arm: BoneGN participantsParticipants who have already been recruited into the CureGN study, or meet its criteria.
Primary Outcome Measure
Change in radius bone strength (failure load) [ Time Frame: Baseline and 12 months ]
Central Contacts
- Maria A. Aponte(212) 342-4678
- Thomas L. Nickolas, MD(212) 305-3273
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Columbia University Irving Medical Center | New York | New York | 10032 | Thomas L. Nickolas, MD (PRINCIPAL_INVESTIGATOR) |
| The Children's Hospital of Philadelphia | Philadelphia | Pennsylvania | 19104 | Michelle R. Denburg, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in New York, NY
Related Studies
- Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.PHASE3 · Recruiting · Novartis Pharmaceuticals · Denver, Colorado
- Rituximab Plus Cyclosporine in Idiopathic Membranous NephropathyPHASE2 · Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- HealthEast Community Hip and Knee Replacement RegistryRecruiting · HealthEast Care System · Saint Paul, Minnesota
- Evaluation of Children With Endocrine and Metabolic-Related ConditionsRecruiting · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Bethesda, Maryland